Landmark Subscription Agreement Represents Strong Commitment and Company's Largest Commercial Sale

FOR IMMEDIATE RELEASE, Haddon Township, NJ—August 30, 2007. GlobalSubmit Inc., a leading developer of software designed exclusively for the review and validation of eCTD global submissions, today announced that a major Biopharm company on the west coast has signed a 3-year subscription agreement with GlobalSubmit. The Biopharm company purchased a subscription for GlobalSubmit's flagship applications, GlobalSubmit REVIEW™and GlobalSubmit VALIDATE™.

The challenge experienced by the Major Biopharm company was to ensure that accurate, quality submissions were prepared and delivered to global agencies in a timely manner. Manual assembly and publishing processes were error-prone, creating incidences of unnecessary rework and wasted time. As the company sought to accelerate new drugs to market, it became clear that a key component of their overall strategy was an effective eCTD review and validation process to ensure compliance. After reviewing many solutions on the market and conducting exhaustive due diligence on competitive solutions, this Major Biopharm selected GlobalSubmit's flagship applications. The 3-year commitment represented their strong commitment to GlobalSubmit's products and their confidence in the solution long term.

In reflecting on the significance of this opportunity, GlobalSubmit's' Chief Executive Officer, Rahul Mistry commented, "Our team endeavors each day to ensure that our clients have the most advanced system on the market for preparation of the eCTD. This opportunity underscores the acceptance of our solution by large multinational players and is confirmation of our strategic direction moving forward. We are delighted that this client and many others have embraced our solutions with confidence."

The Biopharm company will use GlobalSubmit's applications to prepare their first submission during Q4-2007.

 

BACK TO PRESS RELEASES